Introduction
It is well known that approximately 0.5-1% of the worldwide population suffers from epilepsy [1, 2] . About 20-30% of those epilepsies are refractory to pharmacological treatment [1, 3, 4] .
A high percentage of these pharmacoresistant epilepsies are caused by acquired or maldevelopmental cortical lesions. In these cases the development of new antiepileptic drugs (AEDs) has not shown a convincing breakthrough [5] . For many of those patients the surgical removal of these lesions improves the epileptic outcome [6] . However, if the epileptogenic lesion or focus is located in an eloquent brain area, surgery might result in a severe neurological deficit. For these patients, local antiepileptic pharmacotherapy with AED-containing implants could be a treatment option if experimental studies show an effect on epileptic activity.
Most AEDs can suppress any epileptiform discharges, if the drug is concentrated highly enough. However, in systemic pharmacotherapy, systemic adverse effects arising outside of the epileptic focus may prevent sufficiently high AED concentrations in the focus. Several drugs with potential antiepileptic properties cannot reach the epileptogenic brain area because they do not pass the blood-brain barrier [7, 8] . In addition, pharmacoresistant epilepsies are often characterized by multiple drug transporters, which prevent a sufficient AED concentration in the focus [9, 10] . In contrast, local application of AEDs would advantageously reduce systemic side effects, bypass the blood-brain barrier and diminish the effect of multiple drug transporters by higher local AED concentrations [11, 12] .
It was shown that intracerebral or intraventricular application of AEDs as polymer implants or pump systems can reduce seizure frequency or severity [13] [14] [15] [16] . In a rat model with intracortical tetanus toxin (TeT) injection Nilsen et al. [17] showed ictal and interictal activity which was quantified by electrocorticography (ECoG) and electromyography (EMG). Thus, these authors demonstrated this model to be potentially suitable for measuring effects of a local antiepileptic therapy. In further experiments, the same group then described an antiepileptic effect of locally applied gapjunction blockers [18] .
The aim of the present study was to reproduce the described neocortical TeT-injection epilepsy model by Nilsen et al. [17, 18] and establish an ECoG-based quantification method for measuring the epileptic activity in this model. If no stable, quantifiable, epileptic activity could be established, this model should be improved by applying more TeT or multiple TeT-injections; or even combine this model with another neocortical model, as the cobalt(II) chloride (CoCl 2 )-cortical application. Finally, if a stable, quantifiable, epileptic focus would be established, it could prove a potential therapeutic effect of locally applied valproate (VPA)-containing biodegradable polycaprolactone (PCL)-implants.
Materials and methods
Animal experiments were carried out according to the European Community Council Directive (86/609/EEC) and the Declaration of Helsinki and were approved by the local government representative (Regierungsprä sidium Baden-Wuerttemberg, Freiburg, registration no.: 35/9185.81/G-09/10). Sixty-three male Sprague-Dawley rats (Animal facility of the University Medical Center Freiburg) at a mean age of approximately two and a half months were included. Four different treatments were performed: no toxin, single injection of 50-200 ng TeT, triple injections of 50 ng TeT or triple injections of 50 ng TeT plus either 20 mg (initially) or 10 mg (afterwards) CoCl 2 .
Surgery
Surgery was conducted upon sterile conditions. SpragueDawley rats were anesthetized with 1.5-2.5% vol. isoflurane and placed in a stereotactic frame (David Kopf instruments, Tujunga, CA). Borehole trephinations were performed (Proxxon, Niersbach, Germany) and the dura mater was perforated with a needle. Injections were performed over a stainless steel cannula (outer diameter, 0.28 mm), connected to a 2 mL microsyringe (Hamilton, Carl Roth GmbH and Co. KG, Karlsruhe, Germany) via PE-20 tubing with a micropump (World Precision Instruments, Sarasota, USA). For ECoG recordings, teflon-coated silver electrodes (diameter = 0.38 mm, World Precision Instruments, Sarasota, USA) with de-insulated endings were utilized.
In rats without injection, two ECoG electrodes were placed into the M1 region of the right hemisphere (coordinates in relation to the bregma; [19] ): no. 1: anteroposterior (AP) +1.1 mm, mediolateral (ML) À2.5 mm, dorsoventral (DV) À1.0 mm; no. 2: AP +1.1 mm, ML À1.5 mm, DV À1.0 mm. EMG electrodes were inserted into the right and left temporal muscle. The reference and grounding electrode were initially placed into the cerebellum, later placed intraosseously by attachment to implanted screws, which were positioned over the right and left parietal cranium, serving for additional stability. All electrodes were connected to a plug connector, which was embedded in dental cement together with the screws (Paladur 1 , Heraeus, Hanau, Germany). All animals in this investigation received 5 mL 0.9% saline (NaCl) solution subcutaneously during surgery for fluid replacement and 0.05 mg/ kg bodyweight buprenorphine subcutaneously after surgery to prevent postoperative pain.
In rats receiving a single injection of 50-200 ng TeT, the toxin was injected into the M1 area of the right hemisphere (AP +1.1 mm, ML À2.5 mm; DV À1.0 mm) over a 5-min period. Fifty nanogram TeT were solved in 0.5 mL sterile distilled water with 2% bovine serum albumin resulting in a working concentration of 100 ng/mL.
In the case of Evans blue-injection, the toxin was solved in 0.25 mL Evans blue solution and 0.25 mL sterile distilled water with 2% bovine serum albumin. To ensure appropriate toxin diffusion 10 min had to elapse after injection. Then the ECoG and EMG electrodes were positioned as described above.
For rats with triple injections of 50 ng TeT, the additional boreholes were AP +2.1 mm, ML À3.5 mm and AP +0.1 mm, ML À3.5 mm. Each injection was performed over a 10-min period to ensure toxin diffusion. Electrode positioning followed as described above.
For rats with triple injections of 50 ng TeT plus 20 mg or 10 mg CoCl 2 , a hole (5 mm diameter) was carefully drilled with a mill in the skull above the right primary motor cortex (anterior to the bregma, with edges 1 mm lateral to the midline and bordering the coronal suture; Fig. 1A ). Drilling was performed upon steady saline cooling to avoid heat. The dura mater was removed with a sharp miniaturized hook. TeT (50 ng) was injected at injection sites described for the animals with triple injections (Fig. 1B) . After the injections, 20 or 10 mg crystalline CoCl 2 Á6H 2 O was applied onto the cortex. Afterwards, a biodegradable PCL-implant containing either 0.9% NaCl or VPA (10%, w/w each) was placed on top. Finally, the electrodes and the lesion site were covered with cyanoacrylate ( Fig. 1D) , that did not get in touch with the cortical surface. Production and release kinetics of the implants were described in detail by Kammerer et al. [20] . Rats treated with TeT or CoCl 2 showed an increased irritability to noise, physical contact, toward other rats or the hand of the examiner. In addition, they showed an increased aggression. These signs were also described by Brener et al. [21] and Liang et al. [22] .
Recordings, data analysis and histology
In all animals a combined ECoG/EMG-video-monitoring was performed. Recordings started two days after surgery at the earliest to allow recovery and lasted between 90 min and 6 h each. After amplification, data were acquired using a bandpass filter (1 Hz to 5 kHz) and sampled by CED Spike 2 software version 5 (Cambridge Electronic Design Ltd. Cambridge, U.K.). The recordings were analyzed by blinded analyzers, i.e. they did not know which treatment the animal had received. The analysis focused on qualitative and quantitative evaluation of both interictal and ictal activity. Efforts were made not to mistake artifacts for epileptic activity. Interictal epileptic activity was defined as unambiguous epileptiform potentials (EPs) characterized by single or multiple spikes followed by a slow wave and clearly interrupting background activity with respect to amplitude and frequency (Figs. 4B and 5). EPs were previously described after TeT injections [21, 23] . After identification, EPs were counted. By definition, ictal seizure patterns consisted of runs of repetitive spike-waves or rhythmic activity with a dynamic evolution in frequency and topography (Figs. 3 and 4A).
For histology animals were anesthetized intraperitoneally with ketamine, 100 mg/kg, xylazine 5 mg/kg, atropine 0.1 mg/kg in 0.9% NaCl and transcardial perfused for 5 min with artificial cerebrospinal fluid (ACSF: 125 mM NaCl, 25 mM NaHCO 3 , 2.5 mM KCl, 1.25 mM NaH 2 PO 4 , 25 mM C 6 H 12 O 6 , 2 mM CaCl 2 , 1 mM MgCl 2 ), thereafter for 10 min with 4% paraformaldehyde in 0.1 M phosphate buffer at pH 7.3. Immediately after surgical removal the brain specimen were cut perpendicular to the rostro-caudal axis into sections of 50 mm (vibratome VT 1000S, Leica, Bensheim, Germany). Afterwards sections were immersion-stained for 10 min in 0.1% cresyl violet, dehydrated in increasing concentrations of ethanol, xylol and coverslipped (Immu-Mount, ThermoShandon, Dreieich, Germany), for details see ref. [24] . In histological sections the TeT injected rat brains, even those with multiple injections, did not show any morphological lesion, despite the opened scull and perforated dura mater (data not shown), which has been described by multiple authors [17, 18, [21] [22] [23] 25, 26] . In contrast animals treated with neocortical CoCl 2 showed an extended necrosis (Fig. 6 ).
Statistics
Assuming that there is no normal distribution in the amount of EPs/h, a Mann-Whitney U test was performed to compare the effect of VPA and NaCl. A p-value less than 0.05 was considered significant.
Histology
After decapitation, the brain was transferred to 4% paraformaldehyde in 0.4 M phosphate buffer, pH 7.4. Sections (70 mm) were prepared with a vibratome (Leica VT 1000S) for Nissl staining (microscope: Axioplan2, software: AxioVision Rel 4.8 Carl Zeiss, Oberkochen, Germany).
Drugs
Buprenorphine Germany); tetanus toxin (Quadratech Diagnostics Ltd., Epsom, Surrey, U.K.).
Results

Recordings in rats without injection
In 10 animals ECoG electrodes were implanted only to record physiological baseline ECoG. Recorded activity included a basic rhythm consisting of alpha, beta, theta, and delta waves with amplitudes of about 200 mV (Fig. 2) . In contrast to incidental spiking in the control animals reported by Nilsen et al. [17] , no epileptiform activity was observed.
Recordings in rats with single injection of 50-200 ng TeT
In five animals a single dose of 50 ng TeT was intracortically injected into the primary motor cortex of the right hemisphere through a borehole; five animals served as controls and received the same amount of saline (0.9%) instead. The NaCl-injected animals did not show any difference in their behavior or their ECoG and EMG recordings compared with the rats without any injection. In 10 animals we added Evans blue to the TeT injections and saw the intracortical diffusion of the toxin adjacent to the injection site macroscopically. In further 10 animals higher doses up to 200 ng per single injection were administered. Surprisingly, the ECoG and EMGs were not different from the control animals; in particular no constant epileptiform activity was seen. However, there was one single incidental seizure in one animal recorded on the 46th postoperative day (Fig. 3) . The seizure started with facial twitching, followed by clonic movements of the upper and lower limbs. The corresponding rhythmic spike-waves in the ECoG terminated at the same time point, when the 81 s period of the seizure also stopped.
Recordings in rats with triple injections of 50 ng TeT
Eight animals were triple injected intracortically with 50 ng TeT over three boreholes; another animal was triple injected with saline (0.9%). Three of the eight animals with triple TeT injections died shortly after surgery.
Only one of the remaining five triple TeT-injected animals had recurrent seizures (Fig. 4A) . These seizures started on the second postoperative day and lasted until the spontaneous death on the 10th day. The majority of these seizures manifested clinically with clonic movements, including the head and (left) forelimb. There were also some subclinical seizure patterns. In the ECoG and EMG, repetitive spike-waves with increasing frequency were observed. Another animal had a single subclinical seizure, as seen by runs of repetitive spike-waves in the ECoG. Two other animals, of which one had many EPs, displayed only single clonic jerks, which appeared as an involuntary head movement and followed single spike-waves (Fig. 4B) . The last animal with triple TeT injections did not develop any epileptiform activity.
Recordings in rats with triple injections of 50 ng TeT and topically administered CoCl 2
Six animals with triple 50 ng TeT injections additionally received 20 mg CoCl 2 that was placed topically on the neocortical surface. In three of these animals, a VPA-containing PCL-implant was subsequently implanted with contact to the cortical surface. The remaining three animals served as controls; here a sham PCLimplant with NaCl was inserted. Three animals -two with NaClimplants and one with a VPA-implant -died during the first night after surgery. All remaining animals showed EPs in the ECoG recordings (Fig. 5) .
In the NaCl-implant animal, EPs occurred after three days and increased in frequency until the second week, when the frequency amounted to 271.4 EPs/h. After three weeks the EP frequency declined and finally vanished after six weeks. The EP frequency of the two remaining VPA-implant animals peaked (30 and 87 EPs/h) during the first days, then declined gradually until the EPs disappeared after three weeks. In contrast to sole triple TeT injections, triple TeT injections plus CoCl 2 treatment resulted in severe necrosis, spreading from the cortical M1 and M2 region to the basal ganglia (Fig. 6 ). The contralateral hemisphere was not affected. Because of the high mortality in the group with additional 20 mg CoCl 2 , the dose was reduced to 10 mg.
Eight animals were triple injected with 50 ng TeT and 10 mg CoCl 2 was placed neocortically. Thereafter, five animals received sham NaCl-implants and three received VPA-implants. None of these animals died shortly after operation, and all but one (VPAimplant) developed EPs (Fig. 5) . The NaCl-implanted animals showed EPs after the first days and the EP frequency climaxed during or after the second week (9.6-35.0 EPs/h), then gradually declined. In the two VPA-treated animals with EPs, the EP frequency also peaked after few days (341.3 or 15.7 EPs/h after one week, respectively), but already declined during the second week. The last VPA-treated animal did not show any EPs at all. Performing a two-way analysis of variance (factor I: 20 or 10 mg CoCl 2 ; factor II: week 1 or 2), no hints were obtained indicating that results on EP frequency differ between 20 or 10 mg treated animals (factor I: p = 0.8127). Therefore the results of 20 or 10 mg CoCl 2 -treated animals could be pooled together. There was, however, a high interindividual inconsistence in the triple TeT-injected plus CoCl 2 -treated animals regarding the amount of EPs/h. The EP frequencies after the first week in the NaCl-implanted animals (mean: 10.5 EPs/h, standard error of the mean [SEM] 4.8; n = 6; median: 6.4 EPs/h) and VPA-implanted animals (mean: 71.6 EPs/h, SEM 67.5; n = 5; median: 4.6 EPs/h)), therefore, did not differ significantly, though the mean EP frequency of VPA-implant animals was higher than for NaCl-implant animals. The mean and median EP frequency after the second week was, however, significantly higher (p = 0.0303) in the NaCl-implant animals (mean: 53.5 EPs/h, SEM 34.9; median: 22.0 EPs/h) than in the VPA-implant (mean: 4.8 EPs/h, SEM 2.2; median: 6.7 EPs/h) animals (Fig. 7A) .
The time course of EP frequencies were similar within each implant group: The EP frequency of the NaCl-implant animals increased in the second week, while the VPA-implant animals showed a reduction in their EP frequency in the second week. Comparison between the mean increase in EPs/h of the NaClimplant animals (+42.9, SEM 32.7) and the mean decrease in EPs/ h of the VPA-implant animals (À66.8, SEM 65.9) resulted in a significant difference (p = 0.0087) between the rates (Fig. 7B) . This was also true for the 10 mg CoCl 2 treated animals alone (5 NaCl-implanted animals vs. 3 VPA-implanted animals; Fig. 7C ).
Discussion
The aim of our study was to establish an animal model for neocortical epilepsy and to test whether a neocortically placed PCL-implant loaded with an AED would reduce seizure frequency and epileptic ECoG activity. According to the literature, the rat TeT epilepsy model is an appropriate model for chronic neocortical epilepsy [25] . In particular following the publications of Nilsen et al. [17, 18] , we saw the chance to establish a model where ictal and interictal ECoG activity could easily be quantified.
Single injection of TeT
In our hands the model proved to be most difficult in producing stable seizure frequencies or epileptiform ECoG activities. Despite using the same rat strain, TeT source, injection locus and ECoG electrode positioning combined with temporal muscle EMG recordings as Nilsen et al. [17] , we were not able to reproduce their results. After confirmation of the proper injection site with Evans blue and increasing the dose per single injection up to fourfold without any relevant effect, we also tested the efficacy of the used TeT batch in vitro: The toxin clearly reduced the exocytotic release of 3 H-glutamate [27] and of 3 H-GABA [28] in both rat and human neocortical synaptosomes previously loaded with the corresponding transmitter. Nilsen et al. [17] defined epileptic activity as an abrupt change of background ECoG activity, followed by a burst of fast activity evolving into rhythmic spike discharges with higher amplitudes. Spike-waves were not described (though observed previously after TeT injection; [21, 23] ). We were not able to reproduce these features in ECoG activity between our controls and the single-dose, 50-200 ng TeT injected rats. We observed one single tonic-clonic seizure in only one of 25 single TeT-injected rats, whose ECoG during the seizure was unambiguously different to the description of epileptic activity of Nilsen et al. [17] . Barkmeier and colleagues described also in two publications that seizures were extremely rare [29, 30] .
Consecutively, we were also not able to reproduce the differences in the power spectra derived from Fast Fourier Transformation of ECoG activity, which should show power elevation in the 5-20 Hz spectrum [17] . A power elevation in the 5-20 Hz spectrum was seen in control and in injected animals.
In the beginning of our experiments the frequency and amplitude of the EMG activities seldom differed from those of the ECoG recordings. By transposing the grounding and reference electrode intraosseously in the scull, we could improve the ECoG signal (compare Figs. 3 and 5) . We therefore assume that, to some degree, activity recorded in the ECoG channels was actually originating in muscles and registered by both EMG and ECoG electrodes. Therefore, care has to be taken, that muscle activity is not mistaken with ictal activity in the ECoG.
Triple injection of TeT
Because we were not successful with single TeT injections, even when administering higher doses, we enlarged the injection surface area with a triple injection of 50 ng TeT over three burr holes. This enabled us to produce visible seizures and differences in the ECoG activity between TeT-injected animals and controls. Instead of a high frequency activity [17] , we observed clear-cut interictal spike-waves. The rare seizures were characterized by tonic-clonic movements of the extremities and by runs of unambiguous repetitive spike-waves in ECoG recordings. Sometimes clonic jerks following single interictal discharges were observed. In the control group, where the animals received a tripleNaCl-injection, none of the animals showed EPs, therefore we assume that the TeT but not the injection-trauma alone was responsible for the EPs. However, the effect on interictal epileptic activity and seizures after triple injections of TeT varied immensely, and such a high variability prevented the final establishment of an animal model of neocortical epilepsy for the development of new treatment strategies. Therefore we decided to use CoCl 2 in addition to TeT.
Triple injection of TeT plus CoCl 2
It was shown that (heavy) metals can produce epileptic foci (see for instance [31] [32] [33] ). In particular cobalt has been widely utilized in rodent epilepsy models. The cellular mechanism of cobaltinduced epilepsy is not known precisely and many possible explanations for its proconvulsive properties have been proposed: damage of inhibitory neurons [34, 35] , effects on postsynaptic receptors and glutamate uptake [36, 37] , and activity-dependent facilitation of gap junctions [38] . Eder et al. [39] described seizures induced by intrahippocampal implantation of cobalt. Tamargo et al. [40] applied 20 mg CoCl 2 to the rat neocortex, resulting in epileptic spikes in half of the animals, but observed an unspecified high number of rats which died during status epilepticus. Chang et al. [41] showed that implantation of a cobalt wire into the motor cortex of rats produced subacute seizures that were observable for three weeks.
However, despite the fact that these animals developed a local necrosis in the injured area, the stable EP activity decreased after four to six weeks, what was also described by Liang et al. [22] . Unfortunately there is no good explanation why the epileptic activity decreases, since other epilepsy models with morphological lesions, as the hippocampus (e.g. applied kainiate or pilocarpin), showed epileptic activity over a nearly unlimited time. An answer could be, that the structure of a six-neuronallayer-thick neocortex has better antiepileptic repair mechanisms then a three-layered hippocampus. This is supported by the fact, that even TeT injections in hippocampus show EPs for month to years [21, 23, 42, 43] .
In the present study, we did not produce overt seizures with the additional CoCl 2 treatment. In parallel experiments, however, we used a larger TeT dose (225 ng), a medium CoCl 2 dose (15 mg) and also implanted NaCl-or VPA-implants [44] . Then, the animals developed reliable seizures, but also had a high mortality rate, so that quantitative evaluation of ECoG activity was not possible [44] . The CoCl 2 -implanted animals in the present study, however, showed a stable activity of typical EPs, which enabled their quantification. We also observed a high mortality rate among the animals treated with 20 mg CoCl 2 and therefore decided to reduce the dose to 10 mg. None of the animals treated with 10 mg CoCl 2 died, but all except of one (treated with local VPA) developed stable EPs. Fig. 7 . Efficacy of VPA-loaded polymer-implants in reducing the frequency of epileptiform potentials (EPs). (A) The EP frequency after the second week was lower in VPAtreated (n = 5) animals than in saline-treated (n = 6) animals (20 or 10 mg cobalt(II) chloride; CoCl 2 ). (B) The increase or decrease of EPs between the first and second week were compared. Whereas saline-implanted animals (n = 6) showed an increase of EPs/h, VPA-implanted rats (n = 5) showed a decrease. (C) The increase or decrease of EPs differed also between saline-treated (n = 5) and VPA-treated (n = 3) animals without the data from the animals with 20 mg CoCl 2 . Significant differences are indicated by asterisks: *p < 0.05, **p < 0.01; SEM: standard error of the mean.
The stable EP activity upon triple TeT-injections and additional CoCl 2 enabled us to test a local VPA treatment, an antiepileptic drug commonly used in therapy of focal epilepsy. We were able to show a reduction in the rate of EPs after application of VPA directly on the epileptic focus. We hypothesize therefore that local administration of VPA might positively influence not only over-all survival [44] , but also focal epilepsy. However, the rate of EPs was highest during the first two weeks. Therefore we compared the effects of VPA and NaCl polymer implants as an elevation or reduction of the frequency of EPs in this stretch of two weeks, occurring seven and 14 days after the implantation of VPA or NaCl, occurring within one week before and after the implantation operation. The measurements and operations were carried out before the forth week, since we expected and experienced a drop of the frequency of the EPs after this time point.
We admit that in the present study no animals with TeT injections plus CoCl 2 application were studied without PCL implant. However, the fabrication of VPA PCL implants was described previously [20] . We assume no further influence of the biodegradable PCL implants themselves or of their minimal NaCl load. The improbable role of the PCL implants themselves in epileptogenesis (or its prevention), however, has not (yet) been examined systematically.
It was shown by Kammerer et al. [20] in superfusion experiments that the utilized VPA-containing PCL-implants release about 88% of their VPA content in vitro already within the first four days; however, the course of the spiking epileptogenic focus seemed to be affected over a longer period in vivo. In our experiments the EPs frequency only slowly diminished over a two weeks period in animals with VPAimplants. A possible explanation for this could be that the release of VPA out of the polymer matrix might be slower under in vivo conditions (only one side of the polymer in contact with the cortical surface, no steady perfusion) than in an in vitro superfusion chamber.
Conclusions
After establishing a rat model with a stable interictal activity upon triple TeT-injections and additional CoCl 2 , we could prove the in principle antiepileptic effect of local AED treatment. We plan further experiments to show its beneficial effect also on ictal activity including clinically relevant seizures.
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